Invent radiopharmaceuticals for lives

Lays out oncology , neurology and cardiology
Products
Who We Are?

A company ahead of the innovative radiopharmaceuticals in China.

Since 2014, Sinotau started the R&D of next-generation radiopharmaceuticals,which is an innovative pharmaceutical company specializing in the R&D, production, clinical application and marketing of radiopharmaceuticals

About Sinotau
9

Year+

Years of radiopharmaceutical R&D
100

%

Focus on radiopharmaceuticals
3

+

Products
20

+

Pipeline
5

+

R&D and production sites
400

+

Skilled employees
80

+

Authorized Patent
Radiopharmaceutical Structure
 

Chelate

 

Linker

 

Radioisotopes

 

Targeting Molecule

Innovation

From precise diagnostics to targeted therapies, we pioneer next-generation solutions helping improve therapeutic outcomes and the lives of patients.

Sinotau has established differentiated and highly competitive pipeline out of high attention of the R&D innovation and for the sustainable development and theranostic radiopharmaceuticals with the characteristic and diverse innovation ability of our own team.

Pipeline

News

Sinotau is totally engrossed in reseach and development of radiopharmaceuticls. Learn about our latest progress.

Read More

Meilleur, a Joint Venture of Sinotau, That Holds Global Rights to NAV-4694, an ß Amyloid PET Imaging Agent for Alzheimer’s Disease, Is Sold

Recently, Meilleur, a joint venture of Sinotau, that holds global rights to NAV-4694, an ß amyloid PET imaging agent for Alzheimer’s disease, was acquired by Lantheus. Recently published updated guidelines developed by a working group of the National Institute on Aging and the Alzheimer’s Association (NIA-AA) state that Alzheimer’s disease should be defined biologically, using protein-based biomarkers. These guidelines recommend that […]

2024-07-23

Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China  

First Amyloid PET Tracer Received Regulatory Approval in China

2023-10-24

Press Conference on the Regulatory Approval of Florbetaben F18 Injection , the First Beta Amyloid PET Imaging Radiotracer in China, Was Held in Beijing, Opening a New Horizon for Early, Precise, and Non-invasive Diagnosis of Alzheimer’s Disease

Beijing, China, October 17, 2023– the Press Conference on the Regulatory Approval of Florbetaben F 18 Injection, organized by Sinotau Pharmaceutical Group, the leading company of innovative radiopharmaceuticals in China, was successfully held in Beijing. Co-President Mrs. Yanmin Tang, Vice President and Secretary of the Board of Directors Mr. Wenbin Yu, Medical Marketing Director Mr.Xin Wang and other senior leaders of the company […]

2023-10-18

Sinotau Pharmaceutical Group and Blue Earth Diagnostics Ltd collaborate on an agreement to bring an innovative PSMA-targeted PET imaging agent to China, Paving the Way for Integrated Tumor Theranostics

BEIJING, China, 17 October 2023 – Sinotau Pharmaceutical Group and the British molecular imaging company Blue Earth Diagnostics Ltd are announcing an exclusive strategic agreement for the development, production, and commercialization of the innovative PSMA-targeted PET imaging agent flotufolastat (18F) in China. Flotufolastat (18F) is an optimized positron emission tomography (PET) imaging agent designed to target prostate-specific membrane antigen (PSMA) positive lesions, indicated […]

2023-10-17

Sinotau Presents New Products at the 2023 Academic Annual Meeting of the Chinese Society of Nuclear Medicine

BEIJING, China, 21-23 September 2023 – The 2023 Academic Annual Meeting of the Chinese Society of Nuclear Medicine was successfully held in the ancient capital Xi’an, where experts and scholars in nuclear medicine and related fields, excellent companies and industry elites gathered together. As a leading company of innovative radiopharmaceuticals, Sinotau also participated in this event. The conference was organized […]

2023-09-24

Talent Development

We hope to invent radiopharmaceuticals for lives with you following the same heart and ideal. It’s a job, and moreover, it’s common endeavour.
Join Us